Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Other Non-Current Liabilities of $34.1 million for Q1 2026, up 463.27% year-over-year from $6.1 million in Q1 2025, and down 22.24% quarter-over-quarter from $43.9 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $34.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 463.27% year-over-year to $34.1 million; the TTM figure through Mar 2026 stood at $34.1 million (up 463.27% YoY), while the FY2025 annual figure was $43.9 million, up 612.64% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $34.1 million, down from $43.9 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $45.2 million in Q3 2025, with the low at $1000.0 in Q1 2023.
- The 5-year median for Other Non-Current Liabilities is $3.0 million (2022), against an average of $12.9 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities slumped 93.33% in 2022, then jumped 612.64% in 2025.
- Lineage Cell Therapeutics' Other Non-Current Liabilities stood at $2000.0 in 2022, then slumped by 50.0% to $1000.0 in 2023, then jumped by 616000.0% to $6.2 million in 2024, then surged by 612.64% to $43.9 million in 2025, then slipped by 22.24% to $34.1 million in 2026.
- Business Quant data shows LCTX's Other Non-Current Liabilities at $34.1 million in Q1 2026, $43.9 million in Q4 2025, and $45.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.70 Mn |
| Mar 31, 2026 | 34.14 Mn |
| Dec 31, 2025 | 43.91 Mn |
| Sep 30, 2025 | 45.17 Mn |
| Jun 30, 2025 | 18.80 Mn |
| Mar 31, 2025 | 6.06 Mn |
| Dec 31, 2024 | 6.16 Mn |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 2,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 30,000.00 |
| Sep 30, 2018 | 400,000.00 |
| Jun 30, 2018 | 400,000.00 |
| Mar 31, 2018 | 614,000.00 |
| Dec 31, 2017 | 800,000.00 |
| Sep 30, 2017 | 554,000.00 |
| Jun 30, 2017 | 9,000.00 |